Accessibility Menu
Inoviq Ltd logo

Inoviq Ltd(ASX) IIQ

Market CapA$25.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-74%
5 Year-75%
1 Year-56%
1 Month-15%
A$0.18
-2.78%
-0.01Today
Inoviq Ltd last closing stock price
MetricPriceDate
Last closeAUD 0.182026-09-08
Inoviq Ltd stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.78%AUD 0.182026-09-01
1 month-14.63%AUD 0.212026-08-07
3 month-44.44%AUD 0.322026-06-10
Year to date-54.78%AUD 0.392025-12-31
1 year-55.7%AUD 0.402025-09-08
3 year-71.77%AUD 0.622023-09-08
5 year-75%AUD 0.702020-12-04
Since inception-74.23%AUD 0.702016-06-20

Inoviq Ltd Financials at a Glance

Market Cap

A$25.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$2.25M

Net Income (TTM)

-A$14.44M

EPS (TTM)

-A$0.06

P/E Ratio

-3.14

Dividend

A$0.00

Beta (Volatility)

0.02 (Low)

Price

A$0.18

Volume

404,527

Open

A$0.18

Previous Close

A$0.18

Daily Range

A$0.17 - A$0.18

52-Week Range

A$0.17 - A$0.57

Estimated Earnings Date

Feb 19, 2027

IIQ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Inoviq Ltd

INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, focusing on improving cancer detection and treatment. The company operates primarily in Australia and the United States, with a portfolio that includes innovative diagnostic tests and a robust pipeline for future products.

Products and Services
  • hTERT test for bladder cancer screening
  • EXO-NET for exosome capture from liquid biopsies
  • Blood tests under development for ovarian and breast cancer
Growth Outlook
  • Strong pipeline with multiple cancer diagnostic tests in development
  • Recent partnerships enhancing market reach and product validation
  • Increasing demand for non-invasive cancer diagnostics in healthcare
Financial Highlights
  • Recent quarterly revenue of AUD 229,584, showing potential for growth
  • Cash reserves of AUD 13.8 million, providing operational stability
  • Current ratio of 7.56, indicating strong liquidity position
INOVIQ Ltd is positioned in the medical diagnostics and research industry, focusing on innovative solutions for cancer detection. The hTERT test and EXO-NET are key products that address significant market needs. The company’s growth outlook is bolstered by a strong pipeline of diagnostic tests and strategic partnerships that enhance its market presence. Financially, INOVIQ has demonstrated resilience with a solid cash position and a favorable current ratio, indicating the ability to meet short-term obligations. The company’s focus on non-invasive diagnostics aligns with the growing trend in healthcare, making it an intriguing option for potential investors interested in the medical diagnostics sector.
AI Generated • Aug 26, 2026

Industry

Healthcare Providers and Services

CEO

Leearne Maree Hinch, PhD, MBA

Headquarters

Notting Hill, VIC 3168, AU

IIQ Financials

Key Financial Metrics (TTM)

Gross Margin

82.25%

Operating Margin

-2237.36%

Net Income Margin

-1737.11%

Return on Equity

-36.48%

Return on Capital

-50.39%

Return on Assets

-36.70%

Earnings Yield

-31.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$25.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

140.78M

Volume

404.53K

Avg. Volume

374.58K

Financials (TTM)

Gross Profit

-A$1.20M

Operating Income

-A$20.27M

EBITDA

-A$15.82M

Operating Cash Flow

-A$11.04M

Capital Expenditure

-A$272.33K

Free Cash Flow

-A$11.32M

Cash & ST Invst.

A$9.35M

Total Debt

A$289.39K

Inoviq Ltd Performance Analysis

Inoviq Ltd annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 398,19343.9%
20242024-06-30AUD 535,11834.4%
20252025-06-30AUD 547,5752.3%
20262026-06-30AUD 432,047-21.1%
Inoviq Ltd sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-39.3%
Q42025-06-3019.1%
Q22025-12-31-76.7%
Q42026-06-30-11.8%
Inoviq Ltd annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.10-51.3%
20242024-06-30AUD -0.07-27.3%
20252025-06-30AUD -0.06-12.1%
20262026-06-30AUD -0.06-8.7%
Inoviq Ltd sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3110.6%
Q42025-06-3010.9%
Q22025-12-31-9.2%
Q42026-06-3021.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$202.46K

-85.2%

Gross Profit

A$164.43K

+111.7%

Gross Margin

81.21%

N/A

Market Cap

A$25.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.69M

N/A

Employees

15

N/A

Net Income

-A$3.55M

-3.5%

EBITDA

-A$4.65M

-41.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$9.35M

+1.3%

Total Debt

A$289.39K

-62.7%

Accounts Receivable

A$2.02M

+58.8%

Inventory

A$37.74K

+111.6%

Long Term Debt

A$229.00K

+41.1%

Short Term Debt

A$60.39K

-90.2%

Return on Assets

-36.70%

N/A

Return on Invested Capital

-50.36%

N/A

Free Cash Flow

-A$4.33M

-53.7%

Operating Cash Flow

-A$4.20M

-50.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BDX.AXBCAL Diagnostics Limited
A$0.07-2.99%
EMD.AXEmyria Limited
A$0.05+4.35%
RHY.AXRhythm Biosciences Limited
A$0.08-3.53%
LGP.AXLittle Green Pharma Ltd
A$0.07+4.62%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$101.51+0.06%
WYHGWing Yip Food Group
$5.42+0.33%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$43.61-0.06%
NOKNokia
$10.40+0.04%

Questions About IIQ

What is the current price of Inoviq Ltd?

Inoviq Ltd is trading at A$0.18 per share.

What is the 52-week range for Inoviq Ltd?

Over the past 52 weeks, Inoviq Ltd has traded between A$0.17 and A$0.57.

How much debt does Inoviq Ltd have?

As of the most recent reporting period, Inoviq Ltd reported total debt of A$289.39K.

How much cash does Inoviq Ltd have on hand?

Inoviq Ltd reported A$9.35M in cash and cash equivalents in its most recent financial results.

What is Inoviq Ltd’s dividend yield?

Inoviq Ltd does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.